Evercore ISI Group Rates ProQR Therapeutics (PRQR) buy

Evercore ISI Group analyst Gavin Clark-Gartner reiterated a buy rating on ProQR Therapeutics N.V. (PRQR) on June 29, 2026. The firm set a price target of $6.00 for the Nasdaq-listed biotech company. This target represents a major gap compared to the stock's Monday trading price of $1.86, suggesting the firm believes the company is undervalued by the market.

The Price Target Gap

Evercore's $6.00 price target stands out against the stock's recent performance. On June 29, 2026, the firm maintained an outperform rating while actually lifting its target from a previous $5.00. This move signals growing confidence in the company's direction. With the stock priced at $1.86 on Monday, reaching Evercore's goal would require the share price to more than triple. This valuation reflects the high-stakes nature of clinical-stage biotechnology, where success in the lab can lead to rapid shifts in market value.

ProQR Stock Performance

ProQR shares have been relatively steady, trading within a 52-week range of $1.33 to $3.10. At the current price of $1.86, the stock is trading slightly below its 50-day moving average of $1.94 but remains above its 200-day moving average of $1.77. This technical position shows a stock that has found a floor over the last year even as it waits for a catalyst to push it toward the higher targets set by Wall Street analysts.

Recent Earnings

ProQR reported revenue of $18.42 million in its most recent financial update, showing revenue growth of 120.4%. However, as a clinical-stage biotech company, it is common to see losses while research is ongoing. The company reported a net margin of -2.28% and an EPS of -$0.46. With a current ratio of 3.49, the company has enough liquid assets to cover its short-term obligations as it heads toward its next earnings announcement on November 5, 2026.

Analysts Set New Price Targets

Several other firms have weighed in on ProQR recently. On October 1, 2026, H.C. Wainwright & Co. maintained a buy rating but lowered its price target to $8.00 from $12.00. That same day, Chardan Capital kept its buy rating with a $3.00 target. Earlier, on August 20, 2026, B of A Securities started coverage with a buy rating and an $8.00 target. In late June, Jones Trading and Chardan Capital also maintained buy ratings with targets of $10.00 and $3.00, respectively. Across nine analysts, the average price target is $8.22, and the consensus recommendation is a strong buy.

RNA Editing and Collaboration

ProQR Therapeutics is a biotechnology company based in the Netherlands that works on discovery and development of medicines using an RNA editing platform. Their lead projects focus on genetic disorders with high unmet needs, including liver and cardiovascular diseases. A major part of their strategy involves a research and collaboration deal with Eli Lilly and Company, which helps fund the discovery and development of new medicines for genetic disorders in the liver and nervous system.

What to Watch

Investors will likely watch for clinical data updates regarding the Axiomer RNA editing platform, which is the core of ProQR’s value. The significant gap between the current stock price and analyst targets of $6.00 to $10.00 suggests that Wall Street is waiting for proof of progress in the company's pipeline. The next major financial update is expected on November 5, 2026, which may provide more clarity on the company's cash runway and development milestones.